Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Creation of a Collagen Producing Cell Atlas in a Model of Sub-Retinal Fibrosis
Author Affiliations & Notes
  • Sarah Doyle
    The University of Dublin Trinity College, Dublin, Ireland
  • Ema Ozaki
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • Said Aktas
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • Peter D Westenskow
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • Derrick Feenstra
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • Footnotes
    Commercial Relationships   Sarah Doyle Roche, Code F (Financial Support); Ema Ozaki Roche, Code E (Employment); Said Aktas Roche, Code E (Employment); Peter Westenskow Roche, Code E (Employment); Derrick Feenstra Roche, Code E (Employment)
  • Footnotes
    Support  Roche Immunology Incubator Funding
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 766. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Doyle, Ema Ozaki, Said Aktas, Peter D Westenskow, Derrick Feenstra; Creation of a Collagen Producing Cell Atlas in a Model of Sub-Retinal Fibrosis. Invest. Ophthalmol. Vis. Sci. 2024;65(7):766.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Sub-retinal fibrosis, observed at the end stage of neovascular age-related macular degeneration (AMD), is the leading cause of irreversible blindness in AMD. Although the pathogenesis of sub-retinal fibrosis is still unclear, excessive ECM appears to be a key event. Interestingly, the source of excessive ECM proteins, such as collagen, is unknown since fibroblasts are not resident in the healthy retina. Here, we create an atlas of collagen producing cells in the retina using Collagen-1 (Col1a1)-YFP reporter mice. We compare the dynamics of collagen production and cell types involved, in vivo over time, in mice receiving one- and two-stage laser-induced choroidal neovascularization (LiCNV) model to model subretinal wound healing and fibrosis.

Methods : LiCNV was carried out using the Micron IV platform (532nm, 300mW, 100ms, 50um spot size, 3 spots per eye) in 12 week old Col1-YFP reporter mice. After 7 days, a cohort of the mice received a second laser burn directly over the initial lesion. On days 5 (1-stage) and 17 (2-stage), retinal tissue was harvested and retinal pigment epithelium (RPE)/choroid was flatmounted and regions around the CNV lesions were excised. Tissue was digested and live single cells were sorted into YFP+ and YFP- groups using fluorescence-activated cell sorting (FACS). YFP+ vs YFP- RPE/choroid tissue was further analysed by scRNA sequencing using 10x genomics and illumina NextSeq 500 platform.

Results : FACS demonstrated negligible YFP+ cells in the retina compared to the RPE in both LiCNV models, indicating that cells involved in collagen production were not in the retina but in the RPE tissue. scRNAseq analysis revealed that fibroblasts, fibrocytes and pericytes all expressed transcript for Col1a1, however Col1a1 protein expression identified by Col1a1-YFP positivity clearly defined the fibroblast group into Col1a1 high-expressing subsets and Col1a1 low-expressing subsets. We further identified subclusters of disease-associated fibroblasts (DAFs) found only in injured tissue. We also found two well-defined Col1a1-YFP- cell clusters that appear only in the 2-stage fibrosis model.

Conclusions : We have identified a gene signature for DAFs that are found in both 1- and 2-stage LiCNV injury models, and have also identified cell clusters that are found only in the 2-stage model of subretinal fibrosis.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×